MENU
+Compare
RCUS
Stock ticker: NYSE
AS OF
Apr 10, 04:59 PM (EDT)
Price
$7.50
Change
-$0.44 (-5.54%)
Capitalization
840.38M

RCUS Arcus Biosciences Forecast, Technical & Fundamental Analysis

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company... Show more

RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for RCUS with price predictions
Apr 09, 2025

RCUS in -12.93% downward trend, sliding for three consecutive days on April 04, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where RCUS declined for three days, in of 328 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for RCUS entered a downward trend on April 09, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RCUS's RSI Indicator exited the oversold zone, of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where RCUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RCUS just turned positive on April 09, 2025. Looking at past instances where RCUS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

RCUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.733) is normal, around the industry mean (13.320). P/E Ratio (0.000) is within average values for comparable stocks, (62.790). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.760). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (2.773) is also within normal values, averaging (246.160).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RCUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

RCUS is expected to report earnings to -101 cents per share on May 13

Arcus Biosciences RCUS Stock Earnings Reports
Q1'25
Est.
$-1.02
Q4'24
Beat
by $0.20
Q3'24
Beat
by $0.02
Q2'24
Beat
by $0.09
Q1'24
Beat
by $0.95
The last earnings report on February 25 showed earnings per share of -102 cents, beating the estimate of -123 cents. With 915.53K shares outstanding, the current market capitalization sits at 840.38M.
A.I. Advisor
published General Information

General Information

a company which offers pre-clinical drug discovery and development solutions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
3928 Point Eden Way
Phone
+1 510 694-6200
Employees
577
Web
https://www.arcusbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IVFIX3.78N/A
N/A
Federated Hermes Intl Strat Val Div IS
EQPGX18.94N/A
N/A
Fidelity Advisor Equity Growth I
CCAFX32.64N/A
N/A
Calvert Mid-Cap A
BCSFX22.27N/A
N/A
Brown Capital Mgmt Intl Sm Co Instl
MDOBX8.90N/A
N/A
Morgan Stanley Developing Opportunity C

RCUS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with APGE. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then APGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+12.78%
APGE - RCUS
43%
Loosely correlated
+10.46%
ACLX - RCUS
42%
Loosely correlated
+10.37%
ATXS - RCUS
42%
Loosely correlated
+8.80%
IDYA - RCUS
41%
Loosely correlated
+8.69%
XNCR - RCUS
41%
Loosely correlated
+14.86%
More